Patient characteristics, n = 48
| Characteristic . | No. . | % . |
|---|---|---|
| Median age (range) | 62 (23-84) | |
| Age ≥65 y | 20 | 42 |
| Sex | ||
| Male | 37 | 77 |
| Female | 11 | 23 |
| NHL subtype | ||
| FL | 12 | 25 |
| DLCL | 16 | 33 |
| DLCL, GCB type* | 4 | |
| DLCL, ABC type* | 11 | |
| DLCL, unclassifiable | 1 | |
| MCL | 17 | 35 |
| Transformed lymphoma | 2 | 4 |
| MZL | 1 | 2 |
| Number of prior therapies in 43 previously treated patients (range) | 3 (1-10) | |
| Number of previously untreated patients (MCL patients only) | 5 | |
| Refractory to last therapy | 18 | 38 |
| Prior ASCT | 15 | 31 |
| Prior bendamustine | 6 | 13 |
| Ann Arbor stage at study entry | ||
| I-II | 10 | 21 |
| III-IV | 38 | 79 |
| B-symptoms | 11 | 23 |
| Bone marrow involvement | 12 | 25 |
| Bulky disease | ||
| ≥5 cm | 20 | 42 |
| ≥10 cm | 3 | 6 |
| Prognostic score at study entry | ||
| IPI (n = 48) | ||
| 0-1, low risk | 16 | 33 |
| 2, low intermediate risk | 7 | 15 |
| 3, high intermediate risk | 16 | 33 |
| 4-5, high risk | 9 | 19 |
| FLIPI (n = 12) | ||
| 0-1, low risk | 4 | 33 |
| 2, intermediate risk | 5 | 42 |
| 3, poor risk | 3 | 25 |
| MIPI (n = 17) | ||
| <5.7, low risk | 7 | 41 |
| 5.7 to <6.2, intermediate risk | 4 | 24 |
| ≥6.2, high risk | 6 | 35 |
| Characteristic . | No. . | % . |
|---|---|---|
| Median age (range) | 62 (23-84) | |
| Age ≥65 y | 20 | 42 |
| Sex | ||
| Male | 37 | 77 |
| Female | 11 | 23 |
| NHL subtype | ||
| FL | 12 | 25 |
| DLCL | 16 | 33 |
| DLCL, GCB type* | 4 | |
| DLCL, ABC type* | 11 | |
| DLCL, unclassifiable | 1 | |
| MCL | 17 | 35 |
| Transformed lymphoma | 2 | 4 |
| MZL | 1 | 2 |
| Number of prior therapies in 43 previously treated patients (range) | 3 (1-10) | |
| Number of previously untreated patients (MCL patients only) | 5 | |
| Refractory to last therapy | 18 | 38 |
| Prior ASCT | 15 | 31 |
| Prior bendamustine | 6 | 13 |
| Ann Arbor stage at study entry | ||
| I-II | 10 | 21 |
| III-IV | 38 | 79 |
| B-symptoms | 11 | 23 |
| Bone marrow involvement | 12 | 25 |
| Bulky disease | ||
| ≥5 cm | 20 | 42 |
| ≥10 cm | 3 | 6 |
| Prognostic score at study entry | ||
| IPI (n = 48) | ||
| 0-1, low risk | 16 | 33 |
| 2, low intermediate risk | 7 | 15 |
| 3, high intermediate risk | 16 | 33 |
| 4-5, high risk | 9 | 19 |
| FLIPI (n = 12) | ||
| 0-1, low risk | 4 | 33 |
| 2, intermediate risk | 5 | 42 |
| 3, poor risk | 3 | 25 |
| MIPI (n = 17) | ||
| <5.7, low risk | 7 | 41 |
| 5.7 to <6.2, intermediate risk | 4 | 24 |
| ≥6.2, high risk | 6 | 35 |
FLIPI, follicular lymphoma international prognostic index; IPI, international prognostic index; MIPI, mantle cell lymphoma international prognostic index.
Based on immunohistochemical staining by the Hans algorithm.14